

# **Guidelines for the Identification of Beneficiaries with REF Risk Factors in Accordance with the REF Entry and Verification Criteria**

**Version 5**

**Applicable from 1 January 2010**

**Council for Medical Schemes**

The Council for Medical Schemes was established in terms of the Medical Schemes Act 131 of 1998 to provide regulatory oversight to the medical schemes industry.

**9 MARCH 2010**



**COUNCIL FOR MEDICAL SCHEMES**

## Table of Contents

<b>A. Changes made to Version 5 since the publication of Version 4 guidelines published on 06 October 2008. ....</b>	<b>3</b>
<b>1. Introduction .....</b>	<b>4</b>
<b>2. Implementation Date .....</b>	<b>6</b>
<i>Existing CDL Cases .....</i>	<i>6</i>
<i>CDL Cases transferred between Medical Schemes .....</i>	<i>6</i>
<i>All CDL Cases .....</i>	<i>6</i>
<i>Note on Cases Identified with Previous Versions of the Guidelines .....</i>	<i>7</i>
<b>3. Preparation of REF Grids .....</b>	<b>8</b>
<i>General .....</i>	<i>8</i>
<i>Age Bands .....</i>	<i>8</i>
<i>Only Claims paid from a Risk Benefit could result in a case eligible for REF benefits ...</i>	<i>8</i>
<i>CDL Cases .....</i>	<i>8</i>
<i>Multiple Chronic Conditions .....</i>	<i>9</i>
<i>Exclusion of Specific Diseases as Multiple Chronic conditions in the Count Grids .....</i>	<i>10</i>
<i>Maternity .....</i>	<i>11</i>
<i>Beneficiaries without Chronic Diseases .....</i>	<i>11</i>
<i>Grid Prevalence Tables .....</i>	<i>12</i>
<i>Availability of Information from Capitated Providers .....</i>	<i>12</i>
<b>4. Submission of REF Grid Count and REF Grid Prevalence data to the Council for Medical Schemes. ....</b>	<b>13</b>
<b>5. Specific Rules Applicable to the Identification of CDL cases Based on REF Entry and Verification Criteria .....</b>	<b>14</b>
<i>Purpose of Boolean tables in section 6 .....</i>	<i>14</i>
<i>Notes on the collection and archiving of diagnosis related information .....</i>	<i>14</i>
<i>Proof of treatment information is based on claims data .....</i>	<i>15</i>
<i>Two-out-of-three and one-out-of three month rules .....</i>	<i>16</i>
<i>Days of therapy (DOT) Method as alternative to the two-out-of-three and one-out-of three month rules .....</i>	<i>18</i>
<i>Results of Special Investigations .....</i>	<i>18</i>
<i>Specialist Diagnosis required for Certain CDL Conditions .....</i>	<i>18</i>
<i>Ambiguous ICD10 Codes to Identify CDL Cases .....</i>	<i>19</i>
<i>Use of Five-digit ICD10 codes .....</i>	<i>21</i>
<i>Use of ATC and NAPPI codes .....</i>	<i>21</i>
<i>Use of specific medicines to identify CDL cases .....</i>	<i>22</i>
<b>6. Entry and Verification Criteria for CDL Conditions .....</b>	<b>23</b>
Addison's Disease .....	23
Bipolar Mood Disorder .....	24
Bronchiectasis .....	24
Chronic Renal Disease .....	26
Chronic Obstructive Pulmonary Disease .....	27
Coronary Artery Disease .....	28
Crohn's Disease .....	28
Diabetes Insipidus .....	29
Diabetes Mellitus Type 2 .....	30
Diabetes Mellitus Type 1 .....	31
Dysrhythmias .....	32
Epilepsy .....	32

Glaucoma .....	33
Haemophilia .....	33
Hypertension .....	35
Hypothyroidism .....	36
Parkinson's disease .....	37
Schizophrenia .....	39
Systemic Lupus Erythematosus .....	39
Ulcerative Colitis .....	40
HIV / AIDS .....	41
Maternity Codes .....	42
<b>7. ATC Code Descriptions.....</b>	<b>44</b>
<b>8. Details for the Days-of-therapy (DOT) Method .....</b>	<b>48</b>
<i>Days of therapy (DOT) Method .....</i>	<i>48</i>

**A. Changes made to Version 5 since the publication of Version 4 guidelines published on 06 October 2008.**

- i. The determination of age bands in paragraph 3.4 has been improved by adding that the value will always be an integer to assist in the calculation of age-bands.
- ii. The discipline codes for Rheumatologist changed in Q3 2009 from discipline 31 to discipline 18 sub-discipline 12. The affected algorithm, Systemic Lupus Erythematosus has been updated accordingly.
- iii. The admission date as evidence of hospitalisation has been explicitly stated in the proof of treatment rules for Multiple Sclerosis.
- iv. The table layout for Diabetes mellitus, Hyperlipidaemia and Maternity has been simplified for ease of reference. In addition, reference has been made to the version of the Framingham risk score to be used for authorisation in the Hyperlipidaemia algorithm.
- v. The Rheumatoid Arthritis table has been revised resulting in the removal of the disciplines where a diagnosis needs to be confirmed for medicine management other than the Disease Modifying Agents (DMARDS).
- vi. ICD-10 code M05.89: Other seropositive rheumatoid arthritis, unspecified has been inserted to complete the list of ICD-10 codes for Rheumatoid Arthritis.

## 1. Introduction

- 1.1 Successful implementation of the Risk Equalisation Fund (REF) in South Africa is contingent on the accurate identification of beneficiaries with specified risk factors within medical schemes.
- 1.2 Risk factors currently included in the REF methodology are conditions specified in the chronic disease list (CDL)<sup>1</sup>; HIV / AIDS; maternity events; and multiple CDL conditions. The age profile of medical schemes is also used in the REF methodology.
- 1.3 The purpose of this guideline is to define criteria that must be met in the identification of beneficiaries with the above-mentioned risk factors for purposes of application of the REF methodology.
- 1.4 The guidelines serve to ensure that the Risk Equalisation methodology is applied to comparable data received from different medical schemes. Using these criteria, cases, which qualify as beneficiaries of the Risk Equalisation Fund, are identified on a uniform basis in all medical schemes.
- 1.5 The REF Entry and Verification Criteria are intended for this purpose alone, and should not be construed to be limitations or expansions on the entitlements of beneficiaries of medical schemes to minimum benefits prescribed in terms of the Medical Schemes Act (PMBs).
- 1.6 Therefore, there might be instances where a beneficiary is legally entitled to a PMB in respect of a particular condition, but does not qualify for purposes of the REF as a beneficiary with the risk factor pertaining to that condition.
- 1.7 Similarly, certain medicines that are not included in the CDL therapeutic algorithms might be included as proof of treatment to categorise a case as a REF beneficiary. Inclusion of such medicines in the REF Entry and Verification Criteria does not create an entitlement of a beneficiary to access that medicine as a PMB.
- 1.8 These criteria have been developed with the emphasis on the verifiability of cases and will be used to ensure that gaming of the REF is identified and addressed.

---

<sup>1</sup> The CDL is the list of conditions included under the heading "Chronic Conditions" in the Prescribed Minimum Benefit schedule included as Annexure A to the General Regulations made in terms of the Medical Schemes Act, 131 of 1998.

**Applicable to cases reported from 1 January 2010**

- 1.9 These guidelines provide specific clinical codes that serve to identify patients that were treated for CDL conditions.
- 1.10 Initially these guidelines will be reviewed as the need arises, and once stabilised, an annual revision will probably suffice.

## 2. Implementation Date

- 2.1 These criteria (as amended) are applicable from 1 January 2010.

### *Existing CDL Cases*

- 2.2 The diagnoses of cases that have been started on treatment before 1 January 2006 is acceptable to REF.
- 2.3 Other cases must meet the criteria applicable at the time of diagnosis as specified in Table 1 below, or the diagnosis criteria specified in this document

**Table 1: Periods for the application of E&V diagnostic criteria**

<b><i>Period</i></b>	<b><i>Version Applicable</i></b>
Before 2006	None
January 2006 to December 2006	Version 1
January 2007 to December 2007	Version 2.1
January 2008 to December 2008	Version 3.2
January 2009 to December 2009	Version 4

- 2.4 A systematic review of previously diagnosed cases (as specified in Table 1 above) is in the best interest of schemes. The systematic revision of cases may be required in future.

### *New CDL Cases*

- 2.5 All newly diagnosed cases from 1 January 2010 onwards must meet the diagnosis criteria specified in this document (Version 5).

### *CDL Cases transferred between Medical Schemes*

- 2.6 Cases that are on treatment for one of the PMB CDLs when they transfer from one scheme to another must not be compromised and must therefore continue to receive treatment. Similar to the situation in paragraph 2.2, REF therefore has to rely on the “proof of treatment” information rather than on the “diagnosis related information.”

### *All CDL Cases*

- 2.7 All CDL cases, whether existing, newly diagnosed or transferred cases, must meet the “proof of treatment” component stipulated in this, Version 5 of the guidelines from 1 January 2010.

*Note on Cases Identified with Previous Versions of the Guidelines*

- 2.8 Schemes are requested to ensure that their administration systems (as employed by medical scheme administrators, clearing houses, managed care organisations, providers, and others) are capable of applying different sets of criteria strictly on the dates when they become effective. Adequate version control is therefore a requirement.



### 3. Preparation of REF Grids

#### *General*

- 3.1 The REF Grids are submitted separately for each option in the scheme with separate sections for male and female beneficiaries.
- 3.2 A beneficiary is counted for the REF Grid if a beneficiary is entitled to benefits in respect of that month.
- 3.3 Note that service date is used to establish in which month a beneficiary is counted. (See paragraphs 5.7 (page 15) to 5.9 (page 17))

#### *Age Bands*

- 3.4 The age band is determined by taking age last birthday on 1 January. This value will always be an integer. The beneficiary is then placed in the appropriate age band: Under 1, 1-4, 5-9, 10-14... 75-79, 80-84, or 85+. Note that the same age bands are applicable for the statutory returns.
- 3.5 The new-born child is to be incorporated into the age structure by taking the age of the beneficiary as on 1 January of the year of evaluation. The naming of the category as "Under 1" allows for that calculation to produce either a zero or a negative result.

#### *Only Claims paid from a Risk Benefit could result in a case eligible for REF benefits*

- 3.6 All beneficiaries that are reported on in the REF grids must receive their benefits for the relevant condition from a risk pool (as opposed to a personal medical savings account) to qualify for eligibility.

#### *CDL Cases*

- 3.7 Columns 2 to 28 of the REF Grid Count and REF Grid Prevalence are populated based on the REF Entry and Verification criteria for each chronic disease, as specified in this document. Please note that the age band "Under 1" must not to be populated with CDL or HIV information, all beneficiaries below one with CDLs must be included in the "NON" column. Hence, all CDL and HIV columns for under 1 age band must read zero.
- 3.8 For the REF Grid Count each beneficiary must be placed in only one cell in Columns 1 to 28. For a person with two or more CDL conditions (or HIV and one or more CDL

conditions), the scheme may choose the highest cost cell of the combination. A beneficiary with multiple diseases will only be counted once in columns 1 to 28. Thus the total of beneficiaries for columns 1 to 28 must equal the beneficiaries in the option for the period.

- 3.9 Note that with the combination of Cardiac Failure and Cardiomyopathy into one condition, from 1 January 2006, the CHF column must be left blank. All Cardiac Failure and Cardiomyopathy cases must be entered in the CMY column. The contribution table will be adjusted to reflect the new rates.

*Multiple Chronic Conditions*

- 3.10 Once the most expensive disease has been allocated to columns 2 to 28, the multiple disease columns 29 to 31 need to be populated according to the number of chronic diseases. Hence a beneficiary with multiple chronic diseases will reflect twice in the REF Grid Count once for the most expensive disease and once for the number of multiple diseases.

*Exclusion of Specific Diseases as Multiple Chronic conditions in the Count Grids*

3.10.1 Note that, for REF Grid Count purposes, certain CDL diseases that co-occur in the same patient will not be counted as multiple diseases. *(However, if these conditions do co-occur, it must be reflected in the REF Grid Prevalence tables – see paragraph 3.15).* Cases encountered with co-occurring conditions as described in paragraphs 3.10.1.1 to 3.10.1.8 below are not eligible to be counted as multiple diseases in the count grids (CC2, CC3, or CC4 modifiers). The most expensive condition must be counted as a single disease in the REF grid count. The conditions are arranged in descending cost order as determined by the REF Contribution table 2009, which includes the following hierarchy:

Sorted alphabetically		Sorted by Rank	
Disease	Ranking	Disease	Ranking
ADS	25	CRF	1
AST	21	HAE	2
BCE	17	MSS	3
BMD	9	DM1	4
CHF	-	COP	5
CMY	8	SLE	6
COP	5	CSD	7
CRF	1	CHF	-
CSD	7	CMY	8
DBI	13	BMD	9
DM1	4	HIV	10
DM2	18	PAR	11
DYS	16	IHD	12
EPL	14	DBI	13
GLC	23	EPL	14
HAE	2	SCZ	15
HIV	10	DYS	16
HYL	22	BCE	17
HYP	24	DM2	18
IBD	19	IBD	19
IHD	12	RHA	20
MSS	3	AST	21
PAR	11	HYL	22
RHA	20	GLC	23
SCZ	15	HYP	24
SLE	6	ADS	25
TDH	26	TDH	26

3.10.1.1 For count purposes, only one of the following chronic respiratory diseases can be assigned to the same patient: *Chronic Obstructive Pulmonary Disease, Bronchiectasis and Asthma*

**Applicable to cases reported from 1 January 2010**

- 3.10.1.2 For count purposes, only one of the following cardiovascular diseases can be assigned to the same patient: *Cardiomyopathy and Cardiac Failure, Coronary Artery Disease, Dysrhythmias; and Hypertension*
- 3.10.1.3 For count purposes, only one of *Chronic Renal Disease or Hypertension* may be assigned to the same patient.
- 3.10.1.4 For count purposes, only one of the following Gastro Intestinal conditions can be assigned to the same patient: *Crohn's disease or Ulcerative Colitis*
- 3.10.1.5 For count purposes, only one of the following psychiatric conditions can be assigned to the same patient: *Bipolar Mood Disorder or Schizophrenia*
- 3.10.1.6 For count purposes, only one of the following neurological/psychiatric conditions can be assigned to the same patient: *Multiple Sclerosis, Bipolar Mood Disorder, or Epilepsy*
- 3.10.1.7 For count purposes, only one of the following auto-immune conditions can be assigned to the same patient: *Systemic Lupus Erythematosus or Rheumatoid Arthritis*
- 3.10.1.8 Note that, in accordance with the Diabetes Mellitus table in section 6, Diabetes Mellitus Type 1 and Type 2 cannot co-occur.

**Maternity**

- 3.11 The maternity modifier relates to “all the codes that indicate the delivery of a single/multiple foetus either stillborn or alive; following a pregnancy of at least 24 weeks duration”. Codes that apply to the delivery modifier are presented in Table on page 42.
- 3.12 The beneficiary qualifying for the maternity modifier is only entered ONCE — in the month corresponding to the date of admission of the mother into the service facility, or in instances where no admission occurred, the actual date of the confinement is used. The amount payable from the REF is an annual amount and not a monthly amount as with the other modifiers.

**Beneficiaries without Chronic Diseases**

- 3.13 To complete the “NON” column: After completing columns 2 to 28 of the REF Grid Count, beneficiaries that have not been allocated to these columns need to be counted and reflected in column 1. This column now includes **all** beneficiaries from

the “Under 1” age band. This completion of columns 1 to 28 will reflect each beneficiary of an option in only one cell of the grid.

#### *Grid Prevalence Tables*

- 3.14 In the REF Grid Prevalence, the beneficiary is reflected for each one of the diseases he/she has. This rule does not apply to the “Under 1” age band, which must be defaulted to the “NON” column.
- 3.15 The REF Grid Prevalence contains the total number of beneficiaries in the cell for the period. Each beneficiary must be placed in as many cells in Columns 1 to 28 as they have chronic conditions (CDL conditions or HIV). For a person with three CDL conditions the scheme will place the beneficiary in the three relevant columns. Thus the total of beneficiaries for columns 1 to 28 will be more than the beneficiaries in the option for the period.
- 3.16 Note that each of the conditions listed in paragraph 3.10.1 and its sub-paragraphs must be reported on in the REF Prevalence Grid.
- 3.17 The same number of beneficiaries in column 1 of the REF Grid Count should be reflected in column 1 of the REF Grid Prevalence. Hence for both grid types, the “Under 1” age band is defaulted to “NON”.

#### *Availability of Information from Capitated Providers*

- 3.18 Schemes have indicated that they frequently have difficulties to obtain the information required to complete the grids from Managed Care Organisations and from Capitated Providers. It is important to note that:
- 3.18.1 In terms of Regulation 15B (2) (d) it is required that an accredited managed health care organisation has the necessary resources, systems, skills and capacity to render the managed health care services which it wishes to provide. Further, should a managed care organisation comply with Regulations 15D (a) and (c), such an organisation would be capable of providing the medical scheme with the data required for the REF return.
- 3.18.2 Regulation 15E (a) makes it clear that the scheme is not absolved of its responsibility towards members if any other party is in default to provide any service.
- 3.19 Schemes must ensure that their contracts with preferred providers make provision for the availability of the information that is required to prepare the REF grids. (See paragraph 5.19, page 19)

#### 4. Submission of REF Grid Count and REF Grid Prevalence data to the Council for Medical Schemes.

- 4.1 The Statutory Returns Portal on the CMS website accommodates the manual entry of the REF grids. ([www.medicalschemes.com](http://www.medicalschemes.com))
- 4.2 Manual data entry is very time-consuming and leads to many errors during the capturing process.
- 4.3 Schemes are urged to make use of the e-mail facility that has been created to speed up the submission process.
  - 4.3.1 Excel templates will be e-mailed to scheme administrators, who must distribute these to the relevant people that will do the REF submissions. ***Please do not change the file name.***
  - 4.3.2 The layout of these templates is in accordance with the current REF grids – note that separate count and prevalence files need to be completed for each option and period respectively.
  - 4.3.3 -
  - 4.3.4 E-mail the completed files to [refsubmissions@medicalschemes.com](mailto:refsubmissions@medicalschemes.com)
  - 4.3.5 Allow one day for processing and then log on to the statutory returns portal at [www.medicalschemes.com](http://www.medicalschemes.com)
  - 4.3.6 A dialog box will appear that indicates which submissions have been received.

(Depending on the number of submissions received, it might take more than one day after e-mailing the CSV file before it will appear on the list. Should the scheme name not appear within 24 hours after the files have been e-mailed, please send an e-mail to [refqueries@medicalschemes.com](mailto:refqueries@medicalschemes.com))
  - 4.3.7 Click on “Submit.” The system will validate results and will send an e-mail with the errors to the person that has done the submission.
  - 4.3.8 After corrections have been made, the corrected file must be e-mailed to the same address.
  - 4.3.9 Once all the validation criteria have been met, a final copy for signature will be e-mailed to the person doing the submissions.

## **5. Specific Rules Applicable to the Identification of CDL cases Based on REF Entry and Verification Criteria**

### *Purpose of Boolean tables in section 6*

- 5.1 Each of the tables in section 6 consists of a section on diagnosis related information and a section on proof of treatment. To qualify for inclusion as a REF beneficiary, a case must have gone through an authorisation process and must meet both the diagnosis related criteria as well as the proof of treatment criteria.
- 5.2 Authorisation must be performed to collect the diagnosis related information required in the Boolean tables, and does therefore imply a specific process that must be used to ensure that a beneficiary meets all of the requirements listed in the Boolean tables.
- 5.3 The authorisation process cannot happen automatically or without the application of managed care protocols. “Autochronic” methods are therefore not acceptable. Diagnosis information gleaned from claims (medicine or services) is not acceptable for REF.
- 5.4 Note that existing patients on active treatment should not be compromised through the withholding of treatment to prove that they meet the diagnosis related requirements. (See section 2).

### *Notes on the collection and archiving of diagnosis related information*

- 5.5 Diagnosis related information must be recorded in an auditable format; this includes voice recordings, electronic submissions, and written hardcopies.
  - 5.5.1 The provider codes of providers (PCNS or HPCSA codes – see paragraph 5.18) who are diagnosing and/or treating in accordance with the REF Entry and Verification Criteria must be documented in all cases.
  - 5.5.2 Managed care organisations and administrators may provide diagnosis codes on the information provided by the providers (or their employees) specified in section 6. The source documentation (voice recordings, electronic recordings or paper copies) underlying the coding decision must however be archived in an auditable format.
  - 5.5.3 Where the diagnosis can be established by any medical practitioner, and such a provider has not submitted a pre-authorisation request with the given diagnosis, the diagnosis may be communicated to the managed care company or

administrator on behalf of the diagnosing doctor by both employees of such a provider or the pharmacist dispensing medication for such a condition, provided that this diagnostic information is part of the authorisation process (See paragraph 5.2 and paragraph 5.3).

- 5.5.4 Where the diagnosis should be from a provider from a specified group (e.g. specialists), and such a provider has not submitted a pre-authorisation request with the given diagnosis, the treating provider should submit the name of the diagnosing specialist and the diagnosis during the authorisation process.
- 5.5.5 Where the diagnosis should be supported by results of diagnostic tests specified in the REF Entry and Verification Criteria, proof of original laboratory or other test results must be kept. These results could be submitted by the diagnosing or treating provider or the laboratory, if the information is in an auditable format. (See paragraphs 5.5 and 5.16).
- 5.5.6 Hospitalisation or other treatment records may be used as proof of a specific clinical event or diagnosis specified in the REF Entry and Verification Criteria (e.g. Multiple sclerosis in Table , page 36)
- 5.6 The use of diagnosis codes provided on claims alone is not acceptable. The diagnosis related information specified in paragraphs 5.2 and 5.3 is required, implying that a separate authorisation process must exist for each of the conditions specified in section 6.

*Proof of treatment information is based on claims data*

- 5.7 Proof of treatment information must be based on paid claims data.
  - 5.7.1 Procedure codes are used as evidence for the performance of specified procedures in the REF Entry and Verification Criteria (See Chronic Renal Disease table 7 on page 26)
  - 5.7.2 ATC codes are used in the definitions of the REF Entry and Verification Criteria to describe specific medicines. (See paragraphs 5.25 and 5.26).
  - 5.7.3 Note that proof of treatment is valid only if proof of diagnosis has been obtained separately, through an authorisation process; and benefits must be paid from a risk pool. (See paragraphs 3.6 and 5.1 to 5.3). In the instance of DM1 and DM2, an authorisation for either DM1 or DM2 is acceptable (See Table 3, page 30)



*Two-out-of-three and one-out-of-three month rules*

5.7.4 In most instances, evidence is required that a patient has received the specified treatment during at least two preceding calendar months in the three calendar months preceding the current month (the month for which the beneficiary's REF status is established). The schedule below indicates that, to count a beneficiary in December, payment towards treatment must have been made for services rendered in two of the three calendar months of September, October, and November. In instances where treatment occurs less frequently, the beneficiary does not qualify as a REF beneficiary. To clarify:

Application of proof of treatment requirements in instances where proof of treatment is required for two calendar months in the three months preceding the calendar month for which REF eligibility is determined		
Month:	Treatment provided and paid for from a risk pool: (Use service date to allocate to a specific month)	Eligible for Inclusion in the REF grids:
Jan	Yes	No
Feb	Yes	No
Mar	Yes	Yes
Apr	Yes	Yes
May	Yes	Yes
Jun	No	Yes
Jul	No	Yes
Aug	Yes	No
Sep	Yes	No
Oct	Yes	Yes
Nov	No	Yes
Dec	No	Yes
Jan	Yes	No
Feb	Yes	No

- 5.8 Specified conditions require proof of payment for services rendered at least once during the three calendar months preceding the period for which REF eligibility is determined. These conditions and *the specific drugs for which the less frequent issue of medicines is a requirement*, are specified in: Table 2: Asthma, page 23, Table 7: Chronic Obstructive Pulmonary Disease, page 27, Table 6: Chronic Renal Disease, page 26, Table 3 (a): Diabetes Mellitus (Type 2), page 30 and Table 4: Haemophilia, page 33.
- 5.9 For those conditions that need to have proof of treatment less frequently for specific ATC codes, the following table provides an explanation

Application of proof of treatment requirements in instances where proof of treatment is required for one calendar months in the three months preceding the calendar for which REF eligibility is determined		
Month:	Treatment provided and paid for from a risk pool: (Use service date to allocate to a specific month)	Eligible for Inclusion in the REF grids:
Jan	Yes	No
Feb	Yes	Yes
Mar	Yes	Yes
Apr	Yes	Yes
May	Yes	Yes
Jun	No	Yes
Jul	No	Yes
Aug	Yes	Yes
Sep	Yes	Yes
Oct	Yes	Yes
Nov	No	Yes
Dec	No	Yes
Jan	No	Yes
Feb	Yes	No

- 5.10 The tables in section 6 have been written to assist in the development of Boolean statements that will be used by schemes to correctly identify beneficiaries with REF risk factors. These queries must be made available to the CMS and Auditors on request. It is critical that proper version control is applied, since it is likely that these criteria will change at least once a year. The tables describe the logic that must be applied to:

5.10.1 Test whether a case meets the criteria for inclusion as a CDL or HIV/AIDS beneficiary in the REF, and;

5.11 Categorise Diabetes Mellitus cases as either Type 1 or Type 2 diabetes.

*Days of therapy (DOT) Method as alternative to the two-out-of-three and one-out-of three month rules*

5.12 Under specific exceptional circumstances, schemes may apply to the CMS to be exempted from the two-out-of-three and one-out-of three month rules and to apply the DOT method. Such an application must be accompanied by details of the DOT method that is applied, which must conform with the requirements set out in paragraphs 5.13 to 5.14.2 and section 8. The outcome of such an application to the CMS will be communicated to the scheme in writing.

5.13 To qualify for the application of the DOT method, schemes must provide chronic CDL medication to their beneficiaries in larger than 30 days quantities on a regular basis for at least 20% of their beneficiaries, and the total cost of these medicines must exceed 20% of their total CDL medicine costs. For the purposes of this definition the average volume and cost of bulk medication dispensed over the most recent three month period for which data is available must be considered.

5.14 As far as the DOT method is concerned:

5.14.1 The source of the estimated days-of-therapy must be the prescribing clinician, as recorded on the script, and must be verified by comparing the maximum / minimum daily therapeutic quantity with information as provided by reputable sources of DOTs, including SA package insert specifications and peer-reviewed scientific publications.

5.14.2 The DOT estimates must be rounded down to the closest 30 days, and no single issue of medication could have a DOT value exceeding 90 days.

5.15 Section 8 describes the DOT method in detail.

*Results of Special Investigations*

5.16 For Chronic Obstructive Pulmonary Disease, Chronic Renal Disease, Haemophilia, HIV/AIDS, and Hyperlipidaemia, it is required that the results of special investigations are kept by schemes. This information must also be made available to auditors on request but may be in the form of voice recordings or other electronic records.

*Specialist Diagnosis required for Certain CDL Conditions*

- 5.17 Note that the tables in section 6 specify specialists that are required for the diagnosis of the following conditions: Addison's disease, Crohn's disease, Diabetes Insipidus, Genetic Hyperlipidaemia (in the absence of Total Cholesterol values supporting the diagnosis), Multiple Sclerosis, Rheumatoid Arthritis (if the patient is not taking disease modifying medicines) Schizophrenia, Systemic Lupus Erythematosus and Ulcerative Colitis.
- 5.18 The "provider codes" required in section 6 refer to the BHF Discipline list. Health Professions Council for South Africa (HPCSA) numbers should only be used if the provider does not have a PCNS code. In instances where neither an HPCSA nor a PCNS number is available, but the diagnosis was made by a provider employed by a state hospital, the state hospital code is adequate to meet the requirements for specialist diagnosis specified in paragraph 5.17.

*Verifiability and Auditing of Categorisation*

- 5.19 Medical schemes or their contractors must store the information that is required to apply the logic set out in the tables for a period of at least three years. Schemes must ensure that their contracts with third party service providers must specify the period for which the information must be kept, and indicate how this information will be transferred from one contractor to the other where more than one contractor is involved or when contracts are terminated.
- 5.20 This information must be auditable and must be provided to the Council for Medical Schemes and Auditors at request, which might also do on-site audits.

*Ambiguous ICD10 Codes to Identify CDL Cases*

- 5.21 Some of the ICD10 codes specified in the PMB algorithms have been presented in a different context in section 6 to ensure that a case cannot be assigned to more than one CDL condition in each specific instance.
- 5.22 As a rule, if an ICD10 code indicates more than one of the CDL conditions, only the most expensive condition can be selected for the REF Grid Count table, while all conditions must be included in the REF Grid Prevalence tables. In both instances, the proof of treatment criteria must however have been met.
- 5.22.1 *I11.0: Hypertensive heart disease with (congestive) heart failure (or O10.1: Pre-existing hypertensive heart disease complicating pregnancy, childbirth and the puerperium)*

If the “proof of treatment” criteria are met, this condition must be categorised in the REF Grid Count to:  
Cardiac Failure and Cardiomyopathy  
Or  
Hypertension  
(See page 25 for the Cardiac Failure and Cardiomyopathy criteria and page 35 for the Hypertension Criteria)

For the REF Grid Prevalence, these cases must be counted as Cardiac Failure and Cardiomyopathy *and* as Hypertension.

5.22.2 *I12.0: Hypertensive renal disease with renal failure (or O10.2: Pre-existing hypertensive renal disease complicating pregnancy, childbirth and the puerperium)*

If the “proof of treatment” criteria are met, this condition must be categorised in the REF Grid Count to:  
Chronic Renal Disease  
Or  
Hypertension  
(See page 26 for the Chronic Renal Disease criteria and page 35 for the Hypertension Criteria)

For the REF Grid Prevalence, these cases must be counted as Chronic Renal Disease *and* Hypertension.

5.22.3 I13.0: Hypertensive heart and renal disease with (congestive) heart failure (or  
010.3: Pre-existing hypertensive heart and renal disease complicating pregnancy,  
childbirth and the puerperium)

and / or

I13.2: Hypertensive heart and renal disease with both (congestive) heart failure  
and renal failure

If the proof of treatment and diagnosis criteria is met, this condition must be in the REF  
Grid Count categorised to:  
Cardiac Failure and Cardiomyopathy  
Or  
Chronic Renal Disease  
Or  
Hypertension  
(See page 26 for the Chronic Renal Disease criteria and page 35 for the Hypertension  
criteria).

For the REF Grid prevalence, these cases should be counted as Chronic Renal Disease  
and Hypertension and as Cardiac Failure and Cardiomyopathy.

5.22.4 I25.5: Ischaemic Cardiomyopathy

For REF purposes, this code is applicable only to Coronary Artery Disease and is not  
relevant in Cardiac Failure and Cardiomyopathy in the REF Grid Count.

Note that for the REF Grid prevalence, these cases should be counted as only Coronary  
Artery Disease.

#### Use of Five-digit ICD10 codes

5.23 As an interim measure, previous Versions of the REF Entry and Verification criteria  
allowed three digit ICD10 codes in spite of the fact that more specific five-digit codes  
could be used. This was an interim measure to make provision for the gradual  
improvement in the quality of ICD10 coding. Since Version 3 of the criteria requires  
the most specific ICD10 code, in accordance with the industry master ICD 10 table,  
must be used as proof of diagnosis.

#### Use of ATC and NAPPI codes

5.24 Schemes, administrators, providers, and clearing houses make use of NAPPI codes  
to identify and bill for pharmaceuticals.

- 5.25 The REF Entry and Verification Criteria are based on ATC codes, which change less frequently and are widely used. Crosswalks between NAPPI and ATC codes are available from clearing houses and major administrators. Please note the following with regard to ATC codes:
- 5.25.1 The classification of a substance in the ATC system is not a recommendation for use, nor does it imply any judgements about efficacy or relative efficacy of medicines or group of medicines. The ATC system is not applicable for making a diagnosis.
  - 5.25.2 ATC codes may change over the years. An updated version of the ATC Index is issued annually.
  - 5.25.3 The ATC Index is published by the WHO Collaborating Centre for Drug Statistics Methodology and is available at [www.whocc.no](http://www.whocc.no)

*Use of specific medicines to identify CDL cases*

- 5.26 Note that the medicines represented by ATC codes in section 6 do not imply that the CMS recommends that these medicines be used. Neither is it implied that these medicines are required by the regulations on Prescribed Minimum Benefits or the CDL Therapeutic Algorithms published by the Minister of Health. In all instances, the inclusion of a case is based on the information required in the table on “diagnosis – related information” as well as the information related to “proof of treatment.” (See paragraph 5.1)
- 5.27 Note that the use of a medicine to assign a diagnosis to a patient is not acceptable in terms of the criteria specified in section 6. In all instances, an authorisation process (See paragraphs 5.2 and 5.3) together with proof of diagnosis and proof of treatment is required.

## 6. Entry and Verification Criteria for CDL Conditions

Note that each of the conditions specified in Table to Table are subject to the overriding rules on the exclusion of specific multiple diseases specified in paragraph 3.10.1 as well as the rules on ambiguous ICD10 codes in paragraphs 5.21 and 5.22.

**Table 1: Addison's disease**

Addison's Disease				
Diagnosis-related information			AND	Proof of Treatment
Provider code of the diagnosing provider:	AND	ICD10 Codes		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Must be a specialist physician, paediatrician or endocrinologist or diagnosis must be made by a by a provider employed by a state hospital 018000 056001 032000 056002 056000 056003		E27.1	AND	H02AB H02AA02

**Table 2: Asthma**

Asthma						
For count purposes, only one of the following chronic respiratory diseases can be assigned to the same patient: <i>Chronic Obstructive Pulmonary Disease, Bronchiectasis and Asthma</i>						
Diagnosis-related information				AND	Proof of Treatment	
Provider code of the diagnosing provider:	AND	ICD10 Codes (Any of the following)			Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in one calendar month in the three calendar months preceding the current month:	
Any registered medical practitioner		J45.0 J45.1 J45.8	J45.9 J46		R03AC R03AK R03BA	R03BB01 R03CC R03DA04 R03DC



**Table 3: Bipolar Mood Disorder**

<b>Bipolar Mood Disorder</b>					
For count purposes, only one of the following psychiatric conditions can be assigned to the same patient: <i>Bipolar Mood Disorder or Schizophrenia and may not co-occur with Epilepsy or Multiple Sclerosis</i>					
<b>Diagnosis-related information</b>			<b>AND</b>	<b>Proof of Treatment</b>	
Provider code of the diagnosing provider	<b>AND</b>	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Any registered medical practitioner		<div>F31.0</div> <div>F31.1</div> <div>F31.2</div> <div>F31.3</div> <div>F31.4</div>		<div>N05AN01</div> <div>N03AX09</div> <div>N03AF01</div> <div>N03AG01</div>	
		<div>F31.5</div> <div>F31.6</div> <div>F31.7</div> <div>F31.8</div> <div>F31.9</div>			

**Table 4: Bronchiectasis**

<b>Bronchiectasis</b>					
For count purposes, only one of the following chronic respiratory diseases can be assigned to the same patient: <i>Chronic Obstructive Pulmonary Disease, Bronchiectasis and Asthma</i>					
<b>Diagnosis-related information</b>			<b>AND</b>	<b>Proof of Treatment</b>	
Provider code of the diagnosing provider	<b>AND</b>	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Any registered medical practitioner		<div>J47</div> <div>Q33.4</div>		<div>H02AB</div> <div>R03AC</div> <div>R03AK</div> <div>R03BA</div>	<div>R03BB01</div> <div>R03CC</div> <div>R03DA04</div>

**Table 5: Cardiac Failure and Cardiomyopathy**

Cardiac Failure and Cardiomyopathy					
For count purposes, only one of the following cardiovascular diseases can be assigned to the same patient: <i>Cardiomyopathy and Cardiac Failure, Coronary Artery Disease, Dysrhythmias; and Hypertension</i>					
Diagnosis-related information					Proof of Treatment
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)			Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Any registered medical practitioner		I27.9	I42.2		C01AA05
		I50.0	I42.3	C01DA	
		I50.1	I42.4	C02DB	
		I50.9	I42.5	C03	
		I11.0	I42.6	C07	
		I13.0	I42.7	C09	
		I13.2	I42.8		
		I42.0	I42.9		
		I42.1	O10.1		
		O10.3			

Table 6: Chronic Renal Disease

Chronic Renal Disease														
For count purposes , only one of <i>Hypertension</i> or <i>Chronic Renal Disease</i> may be assigned to the same patient														
Diagnosis-related information					AND	Proof of Treatment								
Provider code of the diagnosing provider	AND	Result of Special investigations	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in one calendar month in the three calendar months preceding the current month:								
Any registered medical practitioner		Creatinine clearance value of < 30 ml / min						B05D B05Z B03XA01 V03AE						
									OR	OR				
									A Glomerular Filtration Rate estimate of < 30 ml / min					Evidence of payment for peritoneal or haemodialysis for at least 8 sessions in the preceding three months, as evidenced by any of the following NHRPL or UPFS codes:

**Table 7: Chronic Obstructive Pulmonary Disease**

<b>Chronic Obstructive Pulmonary Disease</b>					
For count purposes, only one of the following chronic respiratory diseases can be assigned to the same patient: <i>Chronic Obstructive Pulmonary Disease, Asthma and Bronchiectasis</i>					
<b>Diagnosis-related information</b>				<b>AND</b>	<b>Proof of Treatment</b>
Any registered medical practitioner	<b>AND</b>	Result of Special investigations	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in one calendar month in the three calendar months preceding the current month:
Any registered medical practitioner		Lung function tests demonstrating FEV1/FVC post-bronchodilator values below 70% and FEV1 post-bronchodilator values of less than 70% of predicted	J43.0 J43.1 J43.2 J43.8 J43.9 J44.0 J44.1 J44.8 J44.9		R03AC R03AK R03BA R03BB R03CC R03DA04

**Table 8: Coronary Artery Disease**

Coronary Artery Disease					
For count purposes, only one of the following cardiovascular diseases can be assigned to the same patient: <i>Cardiomyopathy and Cardiac Failure, Coronary Artery Disease, Dysrhythmias; and Hypertension</i>					
Diagnosis-related information				AND	Proof of Treatment
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)			Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Any registered medical practitioner			I20.0 I20.1 I20.8 I20.9 I25.0 I25.1	I25.2 I25.3 I25.4 I25.5 I25.6 I25.8 I25.9	

**Table 2: Crohn's Disease**

Crohn's Disease					
For count purposes, only one of the following Gastro Intestinal conditions can be assigned to the same patient: <i>Crohn's disease or Ulcerative Colitis</i>					
Diagnosis-related information			AND	Proof of Treatment	
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Must be a specialist physician, paediatrician, surgeon or gastroenterologist or diagnosis must be made by a by a provider employed by a state hospital 018000 056000 032000 056001 042000 056002 019000 056003		K50.0 K50.1 K50.8 K50.9		A07E H02AB J01XD01 J01MA L04AD01 L04AD02	L04AB01 L04AB02 L04AX01 L04AX03 L01BA01 P01AB01

**Table 10: Diabetes Insipidus**

<b>Diabetes Insipidus</b>					
<i>Diagnosis-related information</i>			<b>AND</b>	<i>Proof of Treatment</i>	
Provider code of the diagnosing provider		ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Must be a specialist physician, paediatrician, neurosurgeon, neurologist or endocrinologist or diagnosis must be made by a by a provider employed by a state hospital		E23.2		H01BA	
018000	056000				
032000	056001				
024000	056002				
020000	056003				

Table 3 (a): Diabetes Mellitus (Type 2)

Diabetes Mellitus Type 2						
<p><i>Note:</i></p> <ul style="list-style-type: none"><li>• For REF purposes, Type 1 and Type 2 diabetes cannot occur concurrently.</li><li>• Evidence of use of oral euglycaemic medicines in the preceding three months automatically leads to the classification of a diabetic case as Type 2.</li><li>• Cases meeting the proof of treatment criteria must be counted in accordance with the classification as type 2 in accordance with the rules below, regardless of the type for which authorisation was given.</li></ul>						
Diagnosis-related information					AND	Proof of Treatment
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of use of oral hypoglycaemic or euglycaemic agents in the preceding three months. This includes any product in the A10B ATC category:		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Any registered medical practitioner		E10.0	E11.9	OR		A10B
		E10.1	E12.0	Any ICD10 code indicative of Non-Insulin Dependent Diabetes:		OR
		E10.2	E12.1			
		E10.3	E12.2			
		E10.4	E12.3			
		E10.5	E12.4			
		E10.6	E12.5			
		E10.7	E12.6			
		E10.8	E12.7			
		E10.9	E12.8			
		E11.0	E12.9			
		E11.1	O24.0			
		E11.2	O24.1			
		E11.3	O24.2			
		E11.4	O24.3			
		E11.5	O24.4			
		E11.6	O24.9			
		E11.7				
	E11.8					
					A10A	

**Table 11(b): Diabetes Mellitus (Type 1)**

Diabetes Mellitus Type 1				
<p><i>Note:</i></p> <ul style="list-style-type: none"><li>• For REF purposes, Type 1 and Type 2 diabetes cannot occur concurrently.</li><li>• Where there is <u>only insulin use (ATC A10A)</u>, the doctor's diagnosis (based on the ICD10 codes below) of Type 1 versus Type 2 must be accepted</li><li>• Cases meeting the proof of treatment criteria must be counted in accordance with the classification as type 1 in accordance with the rules below, regardless of the type for which authorisation was given.</li></ul>				
Diagnosis-related information			AND	Proof of Treatment
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Any registered medical practitioner		E10.0 E10.1 E10.2 E10.3 E10.4 E10.5 E10.6 E10.7 E10.8 E10.9		E12.0 E12.1 E12.2 E12.3 E12.4 E12.5 E12.6 E12.7 E12.8 E12.9 O24.0 O24.2 O24.3 O24.4 O24.9



**Table 12: Dysrhythmias**

<b>Dysrhythmias</b>				
For count purposes, only one of the following cardiovascular diseases can be assigned to the same patient: <i>Cardiomyopathy and Cardiac Failure, Coronary Artery Disease, Dysrhythmias; and Hypertension</i>				
<b>Diagnosis-related information</b>			<b>AND</b>	<b>Proof of Treatment</b>
Provider code of the diagnosing provider	<b>AND</b>	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Any registered medical practitioner		I47.2 I48		B01AA03 C01A C01B C07 C08D

**Table 13: Epilepsy**

<b>Epilepsy</b>				
For count purposes, <i>Bipolar Mood Disorder and Multiple Sclerosis may not co-occur with Epilepsy</i>				
<b>Diagnosis-related information</b>			<b>AND</b>	<b>Proof of Treatment</b>
Provider code of the diagnosing provider	<b>AND</b>	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Any registered medical practitioner		G40.0    G40.8 G40.1    G40.9 G40.2    G41.0 G40.3    G41.1 G40.4    G41.2 G40.5    G41.8 G40.6    G41.9 G40.7		N03

Table 14: Glaucoma

Glaucoma					
Diagnosis-related information			AND	Proof of Treatment	
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Any registered medical practitioner		<div>H40.0    H40.5</div> <div>H40.1    H40.6</div> <div>H40.2    H40.8</div> <div>H40.3    H40.9</div> <div>H40.4    Q15.0</div>		S01E	

Table 4: Haemophilia

Haemophilia					
Diagnosis-related information			AND	Proof of Treatment	
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in one calendar month in the three calendar months preceding the current month:	
Any registered medical practitioner		<div>D66    D67</div> <div>AND</div> <div>Laboratory evidence of Factor VIII or IX levels lower than or equal to 5%</div>		<div>B02AA02</div> <div>B02BD02</div> <div>B02BD03</div>	<div>B02BD04</div> <div>B02BD06</div> <div>H01BA</div>

Table 5: Hyperlipidaemia

Hyperlipidaemia									
<p><i>Note:</i></p> <ul style="list-style-type: none"><li>Information supporting the diagnosis must be kept in a format that could be audited. This includes paper copies or the electronic storage of voice recordings that could substantiate the diagnosis, the results of special investigations and the data underlying the risk assessment (Framingham score).</li><li>Only a diagnosis by an endocrinologist will be accepted to diagnose genetic hyperlipidaemias without supporting high Total Cholesterol values</li></ul>									
Diagnosis-related information							AND	Proof of Treatment	
Provider code of the diagnosing provider	AND	Door diagnosis of symptomatic atherosclerotic disease Including any of the following ICD10 codes				ICD10 Codes  (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Any registered medical practitioner.		G45.0	I21.9	I25.8	I65.8	E78.0	C10		
		G45.1	I22.0	I25.9	I65.9	E78.1			
		G45.2	I22.1	I63.0	I66.0	E78.2			
		G45.3	I22.8	I63.1	I66.1	E78.3			
		G45.4	I22.9	I63.2	I66.2	E78.4			
		G45.8	I24.0	I63.3	I66.3	E78.5			
		G45.9	I24.1	I63.4	I66.4				
		I20.0	I24.8	I63.5	I66.8				
		I20.1	I24.9	I63.6	I66.9				
		I20.8	I25.0	I63.8	I67.6				
		I20.9	I25.1	I63.9	I70.0				
		I21.0	I25.2	I64	I70.1				
		I21.1	I25.3	I65.0	I70.2				
		I21.2	I25.4	I65.1	I70.8				
		I21.3	I25.5	I65.2	I70.9				
		I21.4	I25.6	I65.3					
		OR							
		10 year MI risk > 20% and/or risk at age 60 years >30% as per Framingham Risk Score (2001 version)							
		OR							
Genetic hyperlipidaemias diagnosed by:									
	By any registered medical practitioner <b>where</b> TC>7.5mmol/l								
	OR								
	TC> 7 mmol/l	AND	Positive family history of a premature vascular event in a 1 <sup>st</sup> degree male relative < 55 yrs						
			OR						

Applicable to cases reported from 1 January 2010

			TC> 7 mmol/l	AND	Positive family history of a premature vascular event a 1 <sup>st</sup> degree female relative <65 yrs				
			OR						
			The presence of tendon Xantomata						
			OR						
An endocrinologist (PCNS Practise Type: 11801)									

**Table 17: Hypertension**

Hypertension						
For count purposes, only one of the following cardiovascular diseases can be assigned to the same patient: <i>Cardiomyopathy and Cardiac Failure, Coronary Artery Disease, Dysrhythmias; and Hypertension</i>						
For count purposes , only one of <i>Hypertension or Chronic Renal Disease</i> may be assigned to the same patient						
Diagnosis-related information				AND	Proof of Treatment	
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)			Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Any registered medical practitioner		I10 I11.0 I11.9 I12.0 I12.9 I13.0 I13.1 I13.2 I13.9 I15.0 I15.1	I15.2 I15.8 I15.9 O10.0 O10.1 O10.2 O10.3 O10.4 O10.9 O11		C02 C03 C07	C08 C09 G04CA03

Table 68: Hypothyroidism

Hypothyroidism				
Diagnosis-related information			AND	Proof of Treatment
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Any registered medical practitioner		<div>E01.8</div> <div>E02</div> <div>E03.0</div> <div>E03.1</div> <div>E03.2</div> <div>E03.3</div> <div>E03.4</div> <div>E03.5</div> <div>E03.8</div> <div>E03.9</div> <div>E89.0</div>		H03AA

Table 19: Multiple Sclerosis

Multiple Sclerosis				
For count purposes, <i>Bipolar Mood Disorder and Epilepsy may not co-occur with Multiple Sclerosis</i>				
Diagnosis-related information			AND	Proof of Treatment
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Must be a specialist physician, or neurologist or diagnosis must be made by a by a provider employed by a state hospital 018000 020000 056000 056001 056002 056003		G35		<div>L03AB07</div> <div>L03AB08</div> <div>OR</div> <div>Evidence of hospitalisation (admission date) in the preceding three months for acute exacerbation of Multiple Sclerosis (G35)</div>

**Table 20: Parkinson's disease**

Parkinson’s disease				
Diagnosis-related information			AND	Proof of Treatment
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:
Any registered medical practitioner		G20 G21.0 G21.1 G21.2		G21.3 G21.8 G21.9

Table 21: Rheumatoid Arthritis

Rheumatoid Arthritis									
For count purposes, <i>Systemic Lupus Erythematosus</i> may not co-occur with <i>Rheumatoid Arthritis</i>									
<i>Note: Where a patient is not using disease modifying anti-rheumatic medicines, the diagnosis must be verified by a specialist physician or rheumatologist</i>									
Diagnosis-related information						AND	Proof of Treatment		
Provider code of the diagnosing provider	AND	ICD10 Codes					Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:		
		(Any of the following)							
Any registered medical practitioner		M05.00	M05.35	M06.10	M06.45	A07EC01			
	M05.01	M05.36	M06.11	M06.46	H02AB				
	M05.02	M05.37	M06.12	M06.47	L01AA01				
	M05.03	M05.38	M06.13	M06.48	L01BA01				
	M05.04	M05.39	M06.14	M06.49	L04A				
	M05.05	M05.80	M06.15	M06.80	M01AB				
	M05.06	M05.81	M06.16	M06.81	M01AC				
	M05.07	M05.82	M06.19	M06.82	M01AE				
	M05.08	M05.83	M06.17	M06.83	M01AG				
	M05.09	M05.84	M06.18	M06.84	M01AH				
	M05.10	M05.85	M06.20	M06.85	M01C				
	M05.11	M05.86	M06.21	M06.86	P01BA01				
	M05.12	M05.87	M06.22	M06.87					
	M05.13	M05.88	M06.23	M06.88					
	M05.14	M05.89	M06.24	M06.89					
	M05.15	M05.90	M06.25	M06.90					
	M05.16	M05.91	M06.26	M06.91					
	M05.17	M05.92	M06.27	M06.92					
	M05.18	M05.93	M06.28	M06.93					
	M05.19	M05.94	M06.29	M06.94					
	M05.20	M05.95	M06.30	M06.95					
	M05.21	M05.96	M06.31	M06.96					
	M05.22	M05.97	M06.32	M06.97					
	M05.23	M05.98	M06.33	M06.98					
	M05.24	M05.99	M06.34	M06.99					
	M05.25	M06.00	M06.35	M08.00					
	M05.26	M06.01	M06.36	M08.01					
	M05.27	M06.02	M06.37	M08.02					
	M05.28	M06.03	M06.38	M08.03					
	M05.29	M06.04	M06.39	M08.04					
	M05.31	M06.05	M06.40	M08.05					
	M05.30	M06.06	M06.41	M08.06					
	M05.32	M06.07	M06.42	M08.07					
	M05.33	M06.08	M06.43	M08.08					
	M05.34	M06.09	M06.44	M08.09					

**Table 22: Schizophrenia**

<b>Schizophrenia</b>					
For count purposes, only one of the following psychiatric conditions can be assigned to the same patient: <i>Bipolar Mood Disorder or Schizophrenia</i>					
<b>Diagnosis-related information</b>				<b>Proof of Treatment</b>	
Provider code of the diagnosing provider.	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Must be a psychiatrist or paediatric psychiatrist or diagnosis must be made by a by a provider employed by a state hospital 022000 056002 056000 056003 056001		F20.0 F20.1 F20.2 F20.3 F20.4	AND	N05A	

**Table 23: Systemic Lupus Erythematosus**

<b>Systemic Lupus Erythematosus</b>					
For count purposes, <i>Systemic Lupus Erythematosus</i> may not co-occur with <i>Rheumatoid Arthritis</i>					
<b>Diagnosis-related information</b>				<b>Proof of Treatment</b>	
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Must be a specialist physician, paediatrician or rheumatologist or diagnosis must be made by a by a provider employed by a state hospital 018000 056002 018012 056003 032000 031000 056000 056001		M32.0 M32.1 M32.8 M32.9	AND	B01AA03 H02AB L01AA01 L01BA01 L04AD01	L04AD02 L04AA06 L04AX01 M01AB M01AC M01AE M01AG M01AH



Table 24: Ulcerative Colitis

Ulcerative Colitis						
For count purposes, only one of the following Gastro Intestinal conditions can be assigned to the same patient: <i>Crohn's disease or Ulcerative Colitis</i>						
Diagnosis-related information					Proof of Treatment	
Provider code of the diagnosing provider	AND	ICD10 Codes (Any of the following)			Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Must be a specialist physician, surgeon or gastroenterologist or diagnosis must be made by a by a provider employed by a state hospital 042000 018000 019000 056000 056001 056002 056003		K51.0 K51.1 K51.2 K51.3	K51.4 K51.5 K51.8 K51.9		A07E L04AB01 H02AB L04AB02	

Table 25: HIV / AIDS

HIV / AIDS							
<i>Documented proof that demonstrates that the patient qualifies for ART in accordance with the National Antiretroviral Treatment Guidelines must be made available to auditors on request but may be in the form of voice recordings or other electronic records</i>							
Diagnosis-related information						Proof of Treatment	
Provider code of the diagnosing provider	AND	ICD10 Codes(Any of the following)		Documented proof to demonstrate that patient qualifies for ART in accordance with the National Antiretroviral Treatment Guidelines		Evidence of payment of claims for any product included in the ATC categories below, for services / treatment that was provided in two different calendar months in the three calendar months preceding the current month:	
Any registered medical practitioner		B20.0 B20.1 B20.2 B20.3 B20.4 B20.5 B20.6 B20.7 B20.8 B20.9 B21.0 B21.1 B21.2	B21.3 B21.7 B21.8 B21.9 B22.0 B22.1 B22.2 B22.7 B23.0 B23.1 B23.2 B23.8 B24	AND	AND	J05AE J05AF J05AG	

Table 26: Maternity

Maternity Codes		
Admission date		Procedure codes (Any of the following)
		2614, 2615, 2616, 2653
OR		OR
		Diagnosis codes (Any of the following)
Confinement Date	AND	<p>O60.0 Preterm labour without delivery</p> <p>O60.1 Preterm labour with preterm delivery</p> <p>O60.2 Preterm labour with term delivery</p> <p>O61.0 Failed medical induction of labour</p> <p>O61.1 Failed instrumental induction of labour</p> <p>O61.8 Other failed induction of labour</p> <p>O61.9 Failed induction of labour, unspecified</p> <p>O62.0 Primary inadequate contractions</p> <p>O62.1 Secondary uterine inertia</p> <p>O62.2 Other uterine inertia</p> <p>O62.3 Precipitate labour</p> <p>O62.4 Hypertonic, incoordinate, and prolonged uterine contractions</p> <p>O62.8 Other abnormalities of forces of labour</p> <p>O62.9 Abnormality of forces of labour; unspecified</p> <p>O63.0 Prolonged first stage (of labour)</p> <p>O63.1 Prolonged second stage (of labour)</p> <p>O63.2 Delayed delivery of second twin; triplet; etc.</p> <p>O63.9 Long labour; unspecified</p> <p>O64.0 Obstructed labour due to incomplete rotation of fetal head</p> <p>O64.1 Obstructed labour due to breech presentation</p> <p>O64.2 Obstructed labour due to face presentation</p> <p>O64.3 Obstructed labour due to brow presentation</p> <p>O64.4 Obstructed labour due to shoulder presentation</p> <p>O64.5 Obstructed labour due to compound presentation</p> <p>O64.8 Obstructed labour due to other malposition and malpresentation</p> <p>O64.9 Obstructed labour due to malposition and malpresentation; unspecified</p> <p>O65.0 Obstructed labour due to deformed pelvis</p> <p>O65.1 Obstructed labour due to generally contracted pelvis</p> <p>O65.2 Obstructed labour due to pelvic inlet contraction</p> <p>O65.3 Obstructed labour due to pelvic outlet and mid-cavity contra</p> <p>O65.4 Obstructed labour due to fetopelvic disproportion; unspecified</p> <p>O65.5 Obstructed labour due to abnormality of maternal pelvic organs</p> <p>O65.8 Obstructed labour due to other maternal pelvic abnormalities</p> <p>O65.9 Obstructed labour due to maternal pelvic abnormality; unspecified</p> <p>O66.0 Obstructed labour due to shoulder dystocia</p> <p>O66.1 Obstructed labour due to locked twins</p> <p>O66.2 Obstructed labour due to unusually large fetus</p> <p>O66.3 Obstructed labour due to other abnormalities of fetus</p> <p>O66.4 Failed trial of labour; unspecified</p> <p>O66.5 Failed application of vacuum extractor and forceps, unspecified</p> <p>O66.8 Other specified obstructed labour</p> <p>O66.9 Obstructed labour; unspecified</p> <p>O67.0 Intrapartum haemorrhage with coagulation defect</p> <p>O67.8 Other intrapartum haemorrhage</p> <p>O67.9 Intrapartum haemorrhage, unspecified</p> <p>O68.0 Labour and delivery complicated by fetal heart rate anomaly</p> <p>O71.7 Obstetric haematoma of pelvis</p> <p>O71.8 Other specified obstetric trauma</p> <p>O71.9 Obstetric trauma, unspecified</p> <p>O72.0 Third-stage haemorrhage</p> <p>O72.1 Other immediate postpartum haemorrhage</p> <p>O72.2 Delayed and secondary postpartum haemorrhage</p> <p>O72.3 Postpartum coagulation defects</p> <p>O73.0 Retained placenta without haemorrhage</p> <p>O73.1 Retained portions of placenta and membranes, without haemorrhage</p> <p>O74.0 Aspiration pneumonitis due to anaesthesia during labour and delivery</p> <p>O74.1 Other pulmonary complications of anaesthesia during labour and delivery</p> <p>O74.2 Cardiac complications of anaesthesia during labour and delivery</p> <p>O74.3 Central nervous system complications of anaesthesia during labour and delivery</p> <p>O74.4 Toxic reaction to local anaesthesia during labour and delivery</p> <p>O74.6 Other complications of spinal and epidural anaesthesia during labour and delivery</p> <p>O74.7 Failed or difficult intubation during labour and delivery</p> <p>O74.8 Other complications of anaesthesia during labour and delivery</p> <p>O74.9 Complication of anaesthesia during labour and delivery, unspecified</p> <p>O75.0 Maternal distress during labour and delivery</p> <p>O75.1 Shock during or following labour and delivery</p> <p>O75.2 Pyrexia during labour, not elsewhere classified</p> <p>O75.3 Other infection during labour</p> <p>O75.4 Other complications of obstetric surgery and procedures</p> <p>O75.5 Delayed delivery after artificial rupture of membranes</p> <p>O75.6 Delayed delivery after spontaneous or unspecified rupture of</p> <p>O75.7 Vaginal delivery following previous caesarean section</p> <p>O75.6 Delayed delivery after spontaneous or unspecified rupture of membranes</p> <p>O75.7 Vaginal delivery following previous caesarean section</p> <p>O75.8 Other specified complications of labour and delivery</p> <p>O75.9 Complication of labour and delivery, unspecified</p> <p>O80.0 Spontaneous vertex delivery</p> <p>O80.1 Spontaneous breech delivery</p> <p>O80.8 Other single spontaneous delivery</p> <p>O80.9 Single spontaneous delivery, unspecified</p> <p>O81.0 Low forceps delivery</p> <p>O81.1 Mid-cavity forceps delivery</p> <p>O81.2 Mid-cavity forceps with rotation</p> <p>O81.3 Other and unspecified forceps</p>

Applicable to cases reported from 1 January 2010

		<p>O68.1 Labour and delivery complicated by meconium in amniotic fluid</p> <p>O68.2 Labour and delivery complicated by fetal heart rate anomaly</p> <p>O68.3 Labour and delivery complicated by biochemical evidence of f</p> <p>O68.8 Labour and delivery complicated by other evidence of fetal s</p> <p>O68.9 Labour and delivery complicated by fetal stress; unspecified</p> <p>O69.0 Labour and delivery complicated by prolapse of cord</p> <p>O69.1 Labour and delivery complicated by cord around neck; with co</p> <p>O69.2 Labour and delivery complicated by other cord entanglement</p> <p>O69.3 Labour and delivery complicated by short cord</p> <p>O69.4 Labour and delivery complicated by vasa praevia</p> <p>O69.5 Labour and delivery complicated by vascular lesion of cord</p> <p>O69.8 Labour and delivery complicated by other cord complications</p> <p>O69.9 Labour and delivery complicated by cord complication; unspecified</p> <p>O70.0 First degree perineal laceration during delivery</p> <p>O70.1 Second degree perineal laceration during delivery</p> <p>O70.2 Third degree perineal laceration during delivery</p> <p>O70.3 Fourth degree perineal laceration during delivery</p> <p>O70.9 Perineal laceration during delivery, unspecified</p> <p>O71.0 Rupture of uterus before onset of labour</p> <p>O71.1 Rupture of uterus during labour</p> <p>O71.2 Postpartum inversion of uterus</p> <p>O71.3 Obstetric laceration of cervix</p> <p>O71.4 Obstetric high vaginal laceration alone</p> <p>O71.5 Other obstetric injury to pelvic organs</p> <p>O71.6 Obstetric damage to pelvic joints and ligaments</p>	<p>delivery</p> <p>O81.4 Vacuum extractor delivery</p> <p>O81.5 Delivery by combination of forceps and vacuum extractor</p> <p>O82.0 Delivery by elective caesarean section</p> <p>O82.1 Delivery by emergency caesarean section</p> <p>O82.2 Delivery by caesarean hysterectomy</p> <p>O82.8 Other single delivery by caesarean section</p> <p>O82.9 Delivery by caesarean section, unspecified</p> <p>O83.0 Breech extraction</p> <p>O83.1 Other assisted breech delivery</p> <p>O83.2 Other manipulation-assisted delivery</p> <p>O83.3 Delivery of viable fetus in abdominal pregnancy</p> <p>O83.4 Destructive operation for delivery</p> <p>O83.8 Other specified assisted single delivery</p> <p>O83.9 Assisted single delivery, unspecified</p> <p>O84.0 Multiple delivery, all spontaneous</p> <p>O84.1 Multiple delivery, all by forceps and vacuum extractor</p> <p>O84.2 Multiple delivery, all by caesarean section</p> <p>O84.8 Other multiple delivery</p> <p>O84.9 Multiple delivery, unspecified</p> <p>Z37.0 Single live birth</p> <p>Z37.1 Single stillbirth</p> <p>Z37.2 Twins; both liveborn</p> <p>Z37.3 Twins; one liveborn and one stillborn</p> <p>Z37.4 Twins; both stillborn</p> <p>Z37.5 Other multiple births; all liveborn</p> <p>Z37.6 Other multiple births; some liveborn</p> <p>Z37.7 Other multiple births; all stillborn</p> <p>Z37.9 Outcome of delivery; unspecified</p> <p>Z38.0 Singleton; born in hospital</p> <p>Z38.1 Singleton; born outside hospital</p> <p>Z38.2 Singleton; unspecified as to place of birth</p> <p>Z38.3 Twin; born in hospital</p> <p>Z38.4 Twin; born outside hospital</p> <p>Z38.5 Twin; unspecified as to place of birth</p> <p>Z38.6 Other multiple; born in hospital</p> <p>Z38.7 Other multiple; born outside hospital</p> <p>Z38.8 Other multiple; unspecified as to place of birth</p>
--	--	--	--

## 7. ATC Code Descriptions

The purpose of this section is merely to provide descriptions for the codes that are used in and must not be interpreted to append the criteria stipulated in section 6.

Addison's Disease	
H02AB	Glucocorticoids
H02AA02	Fludrocortisone
Asthma	
R03AC	Selective beta-2-adrenoreceptor agonists
R03AK	Adrenergics and other drugs for obstructive airway diseases
R03BA	Glucocorticoids
R03BB01	Ipratropium bromide
R03CC	Selective beta-2-adrenoreceptor agonists
R03DA04	Theophylline
R03DC	Leukotriene receptor antagonists
Bipolar Mood Disorder	
N05AN01	Lithium
N03AX09	Lamotrigine
N03AF01	Carbamazepine
N03AG01	Valproic acid
Bronchiectasis	
H02AB	Glucocorticoids
R03AC	Selective beta-2-adrenoreceptor agonists
R03AK	Adrenergics and other drugs for obstructive airway diseases
R03BA	Glucocorticoids
R03BB01	Ipratropium bromide
R03CC	Selective beta-2-adrenoreceptor agonists
R03DA04	Theophylline
Cardiac Failure and Cardiomyopathy	
C01AA05	Digoxin
C01DA	Organic nitrates
C02DB	Hydrazinophthalazine derivatives
C03	DIURETICS
C07	BETA BLOCKING AGENTS
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

Chronic Renal Disease	
B05D	Peritoneal dialytics
B05Z	Haemodialytics and haemofiltrates
B03XA01	Erythropoietin
V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
Chronic Obstructive Pulmonary Disease	
R03AC	Selective beta-2-adrenoreceptor agonists
R03AK	Adrenergics and other drugs for obstructive airway diseases
R03BA	Glucocorticoids
R03BB	Anticholinergics
R03CC	Selective beta-2-adrenoreceptor agonists
R03DA04	Theophylline
Coronary Artery Disease	
C01DA	Organic nitrates
C07	BETA BLOCKING AGENTS
C08	CALCIUM CHANNEL BLOCKERS
Crohn's Disease	
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS
H02AB	Glucocorticoids
J01XD01	Metronidazole
J01MA	Fluoroquinolones
L04AD01	Ciclosporin
L04AD02	Tacrolimus
L04AB01	Etanercept
L04AB02	Infliximab
L04AX01	Azathioprine
L04AX03	Methotrexate
L01BA01	Methotrexate
P01AB01	Metronidazole
Diabetes Insipidus	
H01BA	Vasopressin and analogues
Diabetes Mellitus	
A10A	INSULINS AND ANALOGUES
A10B	ORAL BLOOD GLUCOSE LOWERING DRUGS

Dysrhythmias	
B01AA03	Warfarin
C01A	CARDIAC GLYCOSIDES
C01B	ANTIARRHYTHMICS, CLASS I AND III
C07	BETA BLOCKING AGENTS
C08D	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
Epilepsy	
N03	ANTIEPILEPTICS
Glaucoma	
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Haemophilia	
B02AA02	Tranexamic acid
B02BD02	Coagulation factor VIII
B02BD03	Factor VIII inhibitor bypassing activity
B02BD06	Von Willebrand factor and coagulation factor VIII in combination
B02BD04	Coagulation factor IX
H01BA	Vasopressin and analogues
Hyperlipidaemia	
C10	SERUM LIPID REDUCING AGENTS
Hypertension	
C02	ANTIHYPERTENSIVES
C03	DIURETICS
C07	BETA BLOCKING AGENTS
C08	CALCIUM CHANNEL BLOCKERS
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
G04CA03	Terazosin
Hypothyroidism	
H03AA	Thyroid hormones
Multiple Sclerosis	
L03AB07	Interferon beta-1a
L03AB08	Interferon beta-1b
Parkinson's disease	
N04	ANTI-PARKINSON DRUGS

Rheumatoid Arthritis	
A07EC01	Sulfasalazine
H02AB	Glucocorticoids
L01AA01	Cyclophosphamide
L01BA01	Methotrexate
L04A	IMMUNOSUPPRESSIVE AGENTS
M01AB	Acetic acid derivatives and related substances
M01AC	Oxicams
M01AE	Propionic acid derivatives
M01AG	Fenamates
M01AH	Coxibs
M01C	SPECIFIC ANTIRHEUMATIC AGENTS
P01BA01	Chloroquine
Schizophrenia	
N05A	ANTIPSYCHOTICS
Systemic Lupus Erythematosus	
B01AA03	Warfarin
H02AB	Glucocorticoids
L01AA01	Cyclophosphamide
L01BA01	Methotrexate
L04AD01	Ciclosporin
L04AD02	Tacrolimus
L04AA06	Mycophenolic acid
L04AX01	Azathioprine
M01AB	Acetic acid derivatives and related substances
M01AC	Oxicams
M01AE	Propionic acid derivatives
M01AG	Fenamates
M01AH	Coxibs
Ulcerative Colitis	
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS
L04AB01	Etanercept
H02AB	Glucocorticoids
L04AB02	Infliximab
HIV / AIDS	
J05AE	Protease inhibitors
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05AG	Non-nucleoside reverse transcriptase inhibitors



## 8. Details for the Days-of-therapy (DOT) Method

- 8.1 This methodology considers the Days of Therapy equivalent of issued medication when determining compliance with medication for REF purposes. This is done in addition to the two-in-three-month and one-in-three-month rules in specified paragraphs 5.7 to 5.9.
- 8.2 This method is applicable only to schemes that have applied in accordance with paragraphs 5.12 to 5.15 to use this additional method.
- 8.3 This section only provides an additional technique to the two-in-three-months and one-in-three-months rules dealing with proof of treatment, and does not affect other elements of these criteria.
- 8.4 Instead of verifying claim frequency based on actual received claims across the three month compliance evaluation period specified paragraphs 5.7 to 5.9, the DOT method is an additional technique that may be applied by qualifying schemes to derive a compliancy status for patients that do not meet the two-in-three-month and one-in-three-month rules.

### *Days of therapy (DOT) Method*

- 8.5 For individuals not meeting the compliance requirements of the two-in-three-month and one-in-three-month rule specified in paragraphs 5.7 to 5.9, matching claims for the preceding five months must be selected. (For example, to determine the REF status for June of a specific year, the DOT method will select claims for medications issued in January to May).
- 8.6 The first step is to round the DOT value down to the nearest multiple of thirty.
- 8.7 For claims received in the **first** month of the selected five month period the DOT value is considered:
  - 8.7.1 If a zero Rounded DOT value is received on claims, a default value of 30 Days is allocated for these claims.
  - 8.7.2 If the Rounded DOT value on the claim is  $\geq 60$  Days, an indicator is set to indicate that a claim was received in month one of the three month compliance evaluation period.
- 8.8 For claims received in the **second** of the selected five months claim selection, the DOT is evaluated:
  - 8.8.1 If the Rounded DOT value is  $\geq 30$  Days, an indicator is set to indicate that a claim was received in month one of three month compliance evaluation period.
  - 8.8.2 If the Rounded DOT value is  $\geq 60$  Days, an indicator is set to indicate that a claim was received in month one **and** two of three month compliance evaluation period.

- 8.9 For claims received in the **third** month of the selected five months claim selection (the first month of the three month compliance evaluation period), the DOT is evaluated:
- 8.9.1 An indicator is set that a claim was received in month one of the three month compliance evaluation period.
  - 8.9.2 If the Rounded DOT value is  $\geq 30$  Days an indicator is set to indicate that a claim was also received in month two of the of the three month compliance evaluation period.
  - 8.9.3 If the Rounded DOT value is  $\geq 60$  Days an indicator is set to indicate that a claim was also received in month two **and** month three of the of the three month compliance evaluation period.
- 8.10 For claims received in the **fourth** month of the selected five months claim selection (the second month of the three month compliance evaluation period), the DOT is evaluated
- 8.10.1 An indicator is set that a claim was received in month two of the three month compliance evaluation period.
  - 8.10.2 If the Rounded DOT value is  $\geq 30$  Days, an indicator is set to indicate that a claim was also received in month three of the three month compliance evaluation period.
  - 8.10.3 If the Rounded DOT value is  $\geq 60$  Days, the same procedure is followed as in 8.10.2.
- 8.11 For claims was received in the **fifth** month of the selected five months claim selection (the third month of the three month compliance evaluation period), the DOT is not considered, but an indicator is set that a claim was received in month three of the three month compliance evaluation period.
- 8.12 Schemes applying the DOT method must submit REF grids after application of the DOT method in accordance with the specifications in section 4, but must also provide the office with additional grids that reflect the compliance in accordance with the standard compliance measurements.

000 – End – 000